Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 52.07%
March 31, 2026 49.64%
December 31, 2025 56.49%
September 30, 2025 51.33%
June 30, 2025 50.71%
March 31, 2025 47.88%
December 31, 2024 49.74%
September 30, 2024 49.71%
June 30, 2024 48.58%
March 31, 2024 46.56%
December 31, 2023 54.43%
September 30, 2023 47.78%
June 30, 2023 46.37%
March 31, 2023 43.12%
December 31, 2022 46.40%
September 30, 2022 45.91%
June 30, 2022 46.83%
March 31, 2022 46.65%
December 31, 2021 49.41%
September 30, 2021 45.31%
June 30, 2021 48.10%
March 31, 2021 46.11%
December 31, 2020 46.00%
September 30, 2020 46.57%
June 30, 2020 45.27%
Date Value
March 31, 2020 46.73%
December 31, 2019 43.65%
September 30, 2019 44.63%
June 30, 2019 45.32%
March 31, 2019 44.73%
December 31, 2018 44.61%
September 30, 2018 44.62%
June 30, 2018 43.25%
March 31, 2018 45.71%
December 31, 2017 42.07%
September 30, 2017 47.18%
June 30, 2017 49.91%
March 31, 2017 50.25%
December 31, 2016 52.22%
September 30, 2016 50.35%
June 30, 2016 57.11%
March 31, 2016 58.02%
December 31, 2015 58.33%
September 30, 2015 57.43%
June 30, 2015 58.31%
March 31, 2015 56.84%
December 31, 2014 55.85%
September 30, 2014 55.54%
June 30, 2014 52.75%
March 31, 2014 53.95%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Bristol Myers Squibb Co. 67.95%
Eli Lilly & Co. 85.78%
Merck & Co., Inc. 71.51%
RedHill Biopharma Ltd. --
Johnson & Johnson 68.73%